Frankfurt - Delayed Quote • EUR
BioCryst Pharmaceuticals, Inc. (BO1.F)
As of April 22 at 11:43 AM GMT+2. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 11 | 12 |
| Avg. Estimate | -0.3 | -0.27 | -1.16 | -0.74 |
| Low Estimate | -0.38 | -0.36 | -1.34 | -1.38 |
| High Estimate | -0.19 | -0.08 | -0.87 | -0.05 |
| Year Ago EPS | -0.26 | -0.34 | -1.09 | -1.16 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 10 | 11 |
| Avg. Estimate | 40.22M | 49.16M | 156.06M | 244.59M |
| Low Estimate | 35M | 40.5M | 145M | 190M |
| High Estimate | 49M | 67M | 181.9M | 319.4M |
| Year Ago Sales | 3.6M | 4.02M | 17.81M | 156.06M |
| Sales Growth (year/est) | 1,017.20% | 1,124.10% | 776.20% | 56.70% |
Earnings History
| CURRENCY IN USD | 9/30/2020 | 12/31/2020 | 3/31/2021 | 6/30/2021 |
|---|---|---|---|---|
| EPS Est. | -0.25 | -0.25 | -0.27 | -0.24 |
| EPS Actual | -0.26 | -0.34 | -0.36 | -0.24 |
| Difference | -0.01 | -0.09 | -0.09 | 0 |
| Surprise % | -4.00% | -36.00% | -33.30% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Current Estimate | -0.3 | -0.27 | -1.16 | -0.74 |
| 7 Days Ago | -0.3 | -0.27 | -1.16 | -0.74 |
| 30 Days Ago | -0.3 | -0.27 | -1.16 | -0.74 |
| 60 Days Ago | -0.27 | -0.24 | -1.11 | -0.74 |
| 90 Days Ago | -0.27 | -0.24 | -1.11 | -0.73 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BO1.F | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -15.40% | -- | -- | 0.20% |
| Next Qtr. | 20.60% | -- | -- | 9.40% |
| Current Year | -6.40% | -- | -- | 4.40% |
| Next Year | 36.20% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 58.10% | -- | -- | 11.07% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/10/2024 |
| Reiterates | Needham: Buy to Buy | 1/8/2024 |
| Reiterates | Needham: Buy to Buy | 11/6/2023 |
| Reiterates | RBC Capital: Outperform to Outperform | 9/25/2023 |
| Upgrade | RBC Capital: Sector Perform to Outperform | 9/18/2023 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 8/4/2023 |
Related Tickers
IVVD Invivyd, Inc.
2.1900
-4.78%
LCTX Lineage Cell Therapeutics, Inc.
1.1400
-0.87%
VIR Vir Biotechnology, Inc.
8.10
+1.89%
VERV Verve Therapeutics, Inc.
6.91
+4.07%
AGEN Agenus Inc.
5.77
+8.66%
BLUE bluebird bio, Inc.
0.9536
-6.51%
ALT Altimmune, Inc.
7.47
+8.10%
MRNS Marinus Pharmaceuticals, Inc.
1.4750
+6.88%
CRSP CRISPR Therapeutics AG
55.66
+1.11%